Loading...
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase a...
Na minha lista:
| Udgivet i: | bioRxiv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Cold Spring Harbor Laboratory
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8312893/ https://ncbi.nlm.nih.gov/pubmed/34312622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.07.21.453274 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|